Literature DB >> 2881943

Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency.

K S Nair.   

Abstract

The physiological significance of the hyperglucagonemia that occurs in patients with many catabolic conditions is unclear. The effect of hyperglucagonemia on resting metabolic rate (RMR) was studied in six normal subjects. Infusion of somatostatin (SRIH; 500 micrograms/h for 210 min) resulted in a 5-fold decrease in plasma C-peptide and a 2-fold decrease in plasma insulin and glucagon concentrations, but did not change RMR significantly. When glucagon (0.2 micrograms/kg X h), was infused with SRIH (500 micrograms/h for 210 min), the decreases in plasma C-peptide and insulin were similar to that during the infusion of SRIH alone, but plasma glucagon increased from 160 +/- 24 (+/- SEM) to 560 +/- 80 pg/mL (P less than 0.001). There was a significant increase in RMR during the entire period (210 min) of glucagon infusion (P less than 0.01). During the last hour of the glucagon plus SRIH infusion, the RMR was 1.38 +/- 0.10 Cal/min, which was 15% higher than the preinfusion RMR (1.19 +/- 0.10 Cal/min; P less than 0.01) and 14% higher than the RMR during the same period when SRIH alone was infused (1.21 +/- 0.11 Cal/min; P less than 0.01). When SRIH and glucagon were infused, protein oxidation (calculated from urinary nitrogen loss) was 52 +/- 5 mg/min, 29% higher than when SRIH alone was infused (40 +/- 5 mg/min; P less than 0.05). These results indicate that hyperglucagonemia during insulin deficiency results in an increase in energy expenditure, which may contribute to the catabolic state in many conditions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2881943     DOI: 10.1210/jcem-64-5-896

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

Review 1.  Minireview: Glucagon in stress and energy homeostasis.

Authors:  B J Jones; T Tan; S R Bloom
Journal:  Endocrinology       Date:  2012-01-31       Impact factor: 4.736

2.  Evidence for a catabolic role of glucagon during an amino acid load.

Authors:  M R Charlton; D B Adey; K S Nair
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 3.  Role of Glucagon in Automated Insulin Delivery.

Authors:  Leah M Wilson; Peter G Jacobs; Jessica R Castle
Journal:  Endocrinol Metab Clin North Am       Date:  2019-12-10       Impact factor: 4.741

Review 4.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

Review 5.  Emerging combinatorial hormone therapies for the treatment of obesity and T2DM.

Authors:  Sharon A Sadry; Daniel J Drucker
Journal:  Nat Rev Endocrinol       Date:  2013-03-12       Impact factor: 43.330

6.  Effects of streptozotocin-induced diabetes and diet on nitrogen loss from organs and on the capacity of urea synthesis in rats.

Authors:  T P Almdal; H Vilstrup
Journal:  Diabetologia       Date:  1987-12       Impact factor: 10.122

Review 7.  Differential control of muscle mass in type 1 and type 2 diabetes mellitus.

Authors:  David Sala; Antonio Zorzano
Journal:  Cell Mol Life Sci       Date:  2015-06-20       Impact factor: 9.261

Review 8.  Protein and energy metabolism in type 1 diabetes.

Authors:  Sadie L Hebert; K Sreekumaran Nair
Journal:  Clin Nutr       Date:  2009-09-27       Impact factor: 7.324

9.  Hormonal control of substrate cycling in humans.

Authors:  H Miyoshi; G I Shulman; E J Peters; M H Wolfe; D Elahi; R R Wolfe
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

10.  The effects of dopamine infusion on the postoperative energy expenditure, metabolism, and catecholamine levels of patients after esophagectomy.

Authors:  M Nakagawa; Y Shinozawa; N Ando; N Aikawa; M Kitajima
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.